Alignment Healthcare, Inc. (NASDAQ:ALHC) CFO Robert Thomas Freeman Sells 14,692 Shares of Stock

Alignment Healthcare, Inc. (NASDAQ:ALHC) CFO Robert Thomas Freeman sold 14,692 shares of the business’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $15.43, for a total value of $226,697.56. Following the transaction, the chief financial officer now directly owns 1,402,862 shares of the company’s stock, valued at approximately $21,646,160.66. This represents a 1.04 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Robert Thomas Freeman also recently made the following trade(s):

• On Thursday, March 6th, Robert Thomas Freeman sold 218,295 shares of Alignment Healthcare stock. The stock was sold at an average price of $15.53, for a total transaction of $3,390,121.35.
• On Tuesday, March 4th, Robert Thomas Freeman sold 250,000 shares of Alignment Healthcare stock. The shares were sold at an average price of $15.58, for a total transaction of $3,895,000.00.

Alignment Healthcare Stock Down 1.3 %

Shares of NASDAQ ALHC opened at $15.50 on Friday. The stock has a market capitalization of $2.97 billion, a PE ratio of -20.13 and a beta of 1.49. The company has a quick ratio of 1.60, a current ratio of 1.60 and a debt-to-equity ratio of 1.82. The firm has a fifty day moving average of $14.30 and a 200-day moving average of $12.36. Alignment Healthcare, Inc. has a 52-week low of $4.46 and a 52-week high of $16.25.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ALHC. William Blair reissued an “outperform” rating on shares of Alignment Healthcare in a research report on Friday, February 28th. JPMorgan Chase & Co. raised their price objective on shares of Alignment Healthcare from $14.00 to $17.00 and gave the stock a “neutral” rating in a research report on Thursday, March 6th. Stephens reissued an “overweight” rating and issued a $17.00 price objective on shares of Alignment Healthcare in a research note on Monday, February 24th. Piper Sandler boosted their target price on Alignment Healthcare from $14.00 to $21.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 4th. Finally, Bank of America increased their price objective on Alignment Healthcare from $15.50 to $18.50 and gave the stock a “buy” rating in a research report on Tuesday, March 4th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $14.83.

Hedge Funds Weigh In On Alignment Healthcare

Several hedge funds and other institutional investors have recently modified their holdings of the company. R Squared Ltd acquired a new position in Alignment Healthcare during the fourth quarter valued at approximately $55,000. RiverPark Advisors LLC acquired a new position in shares of Alignment Healthcare during the fourth quarter worth about $106,000. Tower Research Capital LLC TRC lifted its stake in shares of Alignment Healthcare by 146.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 10,571 shares of the company’s stock worth $119,000 after purchasing an additional 6,286 shares in the last quarter. Ballentine Partners LLC purchased a new stake in shares of Alignment Healthcare in the fourth quarter worth about $121,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Alignment Healthcare during the 3rd quarter valued at about $131,000. 86.19% of the stock is owned by institutional investors and hedge funds.

Alignment Healthcare Company Profile

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.